Regeneron Pharmaceuticals has reported positive data from a Phase III clinical trial of a single dose of its experimental therapy, REGEN-COV, for Covid-19 prevention in uninfected people.

A combination of two monoclonal antibodies, casirivimab and imdevimab, REGEN-COV can potentially hinder Covid-19 infectivity.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The placebo-controlled, double-blind Phase III trial was conducted in collaboration with the National Institute of Allergy and Infectious Diseases.

People from the household of a Covid-19-infected person were enrolled for the trial.

Subjects were categorised into a 1:1 ratio to receive either a 1,200mg dose of REGEN-COV, administered as four subcutaneous injections, or a placebo.

The one dose of the antibody cocktail cut down the Covid-19 risk by 81.6% during the pre-specified follow-up period of two to eight months, thereby maintaining the risk reduction of 81.4% earlier reported in the first month.

Regeneron had reported that the trial had met its primary goal of lowering Covid-19 risk by 81.4% within a month of REGEN-COV administration.

The antibody cocktail continued to offer protection against Covid-19 without needing further doses.

Subjects treated with REGEN-COV had an 81.5% diminished risk of disease development versus placebo during the eight months.

Furthermore, six subjects in the placebo arm were in hospital due to Covid-19 infection as against none in the REGEN-COV arm.

During the eight-month evaluation period, no fatalities linked to Covid-19 were reported in any therapy arm and no new safety signals for the antibody combination were found.

Regeneron president and chief scientific officer George Yancopoulos said: “In this trial, a single dose of REGEN-COV provided long-term protection against Covid-19, including times of particularly high risk from household exposure, and in the longer-term during ongoing broader exposure.

“We intend to rapidly share these additional data with regulatory authorities to help those in most need of protection from Covid-19.”

In September, the World Health Organization included REGEN-COV on the list of therapies for Covid-19 patients.